Tetrathiomolybdate in Hormone Refractory Prostate Cancer - Full Text View

Sponsored by:	University of Michigan
Information provided by:	University of Michigan
ClinicalTrials.gov Identifier:	NCT00150995

Purpose

Purpose: The aim of this clinical trail is to evaluate Tetrathiomolybdate (TM) in the treatment of hormone refractory prostate cancer.

Condition	Intervention	Phase
Prostate Cancer	Drug: tetrathiomolybdate	Phase II

MedlinePlus related topics: Cancer Prostate Cancer

Drug Information available for: Tetrathiomolybdate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Official Title:	A Phase II Trail of Tetrathiomolybdate in Patients With Hormone Refractory Prostate Cancer

Further study details as provided by University of Michigan:

Primary Outcome Measures:

To determine the time to progression and pattern of progression of prostate cancer in patients with androgen-independent prostate cancer treated with tetrathiomolybdate.

Estimated Enrollment:	37
Study Start Date:	May 2001

Detailed Description:

Tetrathiomolybdate or TM, a drug developed for Wilson's Disease, removes copper from the bloodstream. Copper is a key factor in angiogenesis (blood vessel growth)- a process that occurs normally in the body but becomes uncontrolled in cancerous cells. Tetrathiomolybdate essentially wages war against copper, which serves to choke off tumor growth. Realizing the key role of copper in angiogenesis, researchers have begun exploring treatment with Tetrathiomolybdate for different types of cancers. This clinical trial will evaluate the effectiveness of Tetrathiomolybdate in the treatment of patients with hormone refractory prostate cancer. Hormone refractory prostate cancer refers to advanced disease in which the patient no longer responding to conventional hormonal treatment.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Patients must have histologic diagnosis of adenocarcinoma of the prostate with progression following hormonal therapy and antiandrogen withdrawal.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00150995

Locations

United States, Michigan
The University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109

Sponsors and Collaborators

University of Michigan

Investigators

Principal Investigator:

David C. Smith, MD

The University of Michigan Comprehensive Cancer Center

More Information

Study ID Numbers:	UMCC 9962
Study First Received:	September 6, 2005
Last Updated:	September 6, 2005
ClinicalTrials.gov Identifier:	NCT00150995
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Tetrathiomolybdate
Prostatic Diseases
Genital Neoplasms, Male
Molybdenum

Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

Additional relevant MeSH terms:

Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Growth Substances
Physiological Effects of Drugs
Trace Elements
Enzyme Inhibitors
Angiogenesis Inhibitors
Pharmacologic Actions

Neoplasms
Neoplasms by Site
Therapeutic Uses
Micronutrients
Angiogenesis Modulating Agents
Growth Inhibitors
Chelating Agents

ClinicalTrials.gov processed this record on January 16, 2009